Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.67 |
| ▸ | IL2 | P60568 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | STAT3 | P40763 | 13/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29425877 | 1.00 | BACE1 (0.67) | BACE1IL2MAPTPOLBKDM4E | |
| SCHEMBL29426034 | 1.00 | BACE1 (0.67) | BACE1IL2MAPTPOLBKDM4E | |
| Oleoside Dimethyl Ester SCHEMBL19831306 | 0.92 | BACE1 (0.71) | BACE1IL2MAPTPOLBKDM4E | |
| Oleoside Dimethyl Ester SCHEMBL21324467 | 0.92 | BACE1 (0.71) | BACE1IL2MAPTPOLBKDM4E | |
| Oleoside Dimethyl Ester SCHEMBL29425902 | 0.92 | BACE1 (0.71) | BACE1IL2MAPTPOLBKDM4E | |
| SCHEMBL16307160 | 0.91 | BACE1 (0.66) | BACE1IL2MAPTPOLBKDM4E | |
| SCHEMBL23521502 | 0.91 | BACE1 (0.56) | BACE1IL2MAPTPOLBKDM4E | |
| SCHEMBL23559520 | 0.91 | BACE1 (0.56) | BACE1IL2MAPTPOLBKDM4E | |
| SCHEMBL12405934 | 0.87 | BACE1 (0.75) | BACE1IL2MAPTPOLBKDM4E | |
| Excelside A SCHEMBL29425857 | 0.87 | IL2 (0.72) | BACE1IL2MAPTPOLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11590189-B2 | Therapeutic use of a Fraximus augustifolia extract | NATUREX S.A. (FR) | 2023-02-28 | — | — | US | claimed |
| US-20210177023-A1 | COMPOUNDS FOR SWEETNESS ENHANCEMENT | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 2021-06-17 | — | — | US | claimed |
| US-20260123641-A1 | PROCESSES AND METHODS FOR PRODUCING AN EDIBLE CREAM FROM OLIVES | MASANES AUTARD TOMAS (US) | 2026-05-07 | — | — | US | disclosed |
| US-20250194621-A1 | PROCESSES AND METHODS FOR PRODUCING AN EDIBLE CREAM FROM OLIVES | M.A.T SRL (AR) | 2025-06-19 | — | — | US | disclosed |
| US-12232505-B2 | Processes and methods for producing an edible cream from olives | MASANÉS AUTARD, TOMÁS | 2025-02-25 | — | — | US | disclosed |
| CN-113884590-B | Analysis method capable of simultaneously and rapidly detecting phenols and triterpenes in olive processing byproducts | 中国林业科学研究院林产化学工业研究所 | 2025-02-18 | — | — | CN | disclosed |
| US-11590189-B2 | Therapeutic use of a Fraximus augustifolia extract | NATUREX S.A. (FR) | 2023-02-28 | — | — | US | disclosed |
| EP-4135529-A1 | PROCESSES AND METHODS FOR PRODUCING AN EDIBLE CREAM FROM OLIVES | Masanés Autard, Tomas (US) | 2023-02-22 | — | — | EP | disclosed |
| CN-115697072-A | Process and method for producing edible creams from olives | 托马斯·马萨内斯·奥塔尔 | 2023-02-03 | — | — | CN | disclosed |
| EP-3409766-B1 | AN ESTERASE THAT IS CAPABLE OF CONVERTING IRIDOIDS AND SECO-IRIDOIDS | N ZYME BIOTEC GMBH (DE) | 2022-03-09 | — | — | EP | disclosed |
| US-20210177023-A1 | COMPOUNDS FOR SWEETNESS ENHANCEMENT | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 2021-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11590189-B2 | Therapeutic use of a Fraximus augustifolia extract | FABP1, FXR1, FXR2 | BACE1 3193/4885IL2 4744/4885MAPT 2927/4885 |
| US-20260123641-A1 | PROCESSES AND METHODS FOR PRODUCING AN EDIBLE CREAM FROM OLIVES | CD69, SORD, CUTA | BACE1 1890/4885IL2 1518/4885MAPT 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.